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ABSTRACT
Objectives: To compare the ability of
ophthalmologists versus optometrists to correctly
classify retinal lesions due to neovascular age-related
macular degeneration (nAMD).
Design: Randomised balanced incomplete block trial.
Optometrists in the community and ophthalmologists
in the Hospital Eye Service classified lesions from
vignettes comprising clinical information, colour
fundus photographs and optical coherence
tomographic images. Participants’ classifications were
validated against experts’ classifications (reference
standard).
Setting: Internet-based application.
Participants: Ophthalmologists with experience in the
age-related macular degeneration service; fully
qualified optometrists not participating in nAMD shared
care.
Interventions: The trial emulated a conventional trial
comparing optometrists’ and ophthalmologists’
decision-making, but vignettes, not patients, were
assessed. Therefore, there were no interventions and
the trial was virtual. Participants received training
before assessing vignettes.
Main outcome measures: Primary outcome—
correct classification of the activity status of a lesion
based on a vignette, compared with a reference standard.
Secondary outcomes—potentially sight-threatening
errors, judgements about specific lesion components
and participants’ confidence in their decisions.
Results: In total, 155 participants registered for the
trial; 96 (48 in each group) completed all assessments
and formed the analysis population. Optometrists and
ophthalmologists achieved 1702/2016 (84.4%) and
1722/2016 (85.4%) correct classifications, respectively
(OR 0.91, 95% CI 0.66 to 1.25; p=0.543).
Optometrists’ decision-making was non-inferior to
ophthalmologists’ with respect to the prespecified limit
of 10% absolute difference (0.298 on the odds scale).
Optometrists and ophthalmologists made similar
numbers of sight-threatening errors (57/994 (5.7%) vs
62/994 (6.2%), OR 0.93, 95% CI 0.55 to 1.57;
p=0.789). Ophthalmologists assessed lesion
components as present less often than optometrists
and were more confident about their classifications
than optometrists.
Conclusions: Optometrists’ ability to make nAMD
retreatment decisions from vignettes is not inferior to
ophthalmologists’ ability. Shared care with optometrists
monitoring quiescent nAMD lesions has the potential
to reduce workload in hospitals.
Trial registration number: ISRCTN07479761;
pre-results registration.
Strengths and limitations of this study
▪ The virtual design allowed us to do the trial
quickly and efficiently, recruiting ophthalmolo-
gists and optometrists from across the UK; vign-
ettes were created from information for actual
patients, collected for a randomised trial.
▪ Virtual decision-making is different from
face-to-face decision-making in a clinic but
similar to how some hospitals are managing
their workload.
▪ Optometrists would have liked more training but
nevertheless achieved non-inferior performance
with respect to the prespecified inferiority
margin.
▪ Vignettes were created using images obtained
with spectral domain systems that afforded
poorer quality visualisation than currently.
▪ Groups of ophthalmologists and optometrists
had different average durations since obtaining
the qualification that made them eligible to take
part but were trained identically.
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INTRODUCTION
Wet or neovascular age-related macular degeneration
(nAMD) is a common eye condition that causes severe
sight loss and blindness. Lesions develop due to new
blood vessels growing from the choroid or within the
retina, which breach the normal tissue barriers and
come to lie within the subpigment epithelial and subre-
tina. nAMD is treated by intravitreal injections of antivas-
cular endothelial growth factor drugs,1 which inhibit
vascular endothelial growth factor, until the lesion
becomes dormant. However, dormant lesions can reacti-
vate, and therefore, patients need to be monitored at
regular hospital visits. These visits involve visual acuity
checks, clinical examination and optical coherence
tomograms (OCT). Treatment is restarted if a lesion has
reactivated.
Regular monthly review in the UK Hospital Eye
Service (HES) blocks clinic space, uses valuable
resources, is expensive and is also burdensome to the
patients and their carers. The total number of patients
with nAMD requiring regular monitoring has not yet
reached a steady state because, based on current experi-
ence, monitoring needs to continue until vision
becomes so poor that a patient declines to attend or
dies. Therefore, some hospitals are struggling to provide
clinic appointments at recommended intervals. This situ-
ation has prompted service providers to explore innova-
tive models of service provision.
‘Shared care’ between optometrists in private practice
in the community and the HES is reasonably well estab-
lished for eye conditions other than nAMD, such as
glaucoma.2 3 A recent review4 showed a number of scen-
arios used to increase the capacity of nAMD services
across the UK; many scenarios involved extended roles
for optometrists and nurse practitioners but only when
working within the HES. Other studies have evaluated
the potential of capturing OCTs in an outreach service,
but these still involve assessments by ophthalmologists
working in the HES.5 6
The Effectiveness of Community versus Hospital Eye
Service follow-up for patients with quiescent nAMD
(ECHoES) trial was designed to test the hypothesis that,
after uniform training, decisions about the reactivation
of nAMD lesions previously classiﬁed as quiescent made
by optometrists working in the community are not infer-
ior to decisions made by ophthalmologists working in
the HES.
METHODS
Study design
The ECHoES trial is a non-inferiority trial designed to
emulate a parallel group design. Decisions about the
reactivation status of lesions were made from vignettes,
consisting of sets of retinal images (colour and spectral
domain OCT) with accompanying clinical information,
rather than by examining actual patients. Retreatment
decision-making on the basis of review of images, in the
absence of the patient, is a strategy that is increasingly
being used by the HES to improve the efﬁciency of
nAMD clinics. A NHS Research Ethics committee gave a
favourable ethical opinion of the study on 14 May 2013
(reference 13/EM/0199). The trial is registered
(ISRCTN07479761; pre-results registration). The study
sponsor was the Queen’s University Belfast. The study
was conducted in accordance with the principles of the
International Conference on Harmonisation of Good
Clinical Practice under the oversight of the study
sponsor.
Ninety-six participants (48 optometrists and 48 ophthal-
mologists) each assessed 42 vignettes. A randomised
balanced incomplete block design was used,7 8 with each
vignette assessed by seven participants in each professional
group. A secure web-based application was developed to
allow participants to take part in the trial remotely; a dem-
onstration can be viewed at http://www.echoestrial.org/
demo/Account/Register.aspx. Further details have been
described elsewhere (http://www.nets.nihr.ac.uk/__data/
assets/pdf_ﬁle/0007/81196/PRO-11-129-195.pdf; accessed
19 November 2015).9
Vignettes
A database containing 288 vignettes was created from
the clinical and image repository of a previously con-
ducted clinical trial (HTA ref.: 07/36/01;
ISRCTN92166560; pre-results registration10 11); this
number of vignettes is explained below. The vignette
consisted of a brief clinical summary that provided a
patient’s age, gender, cardiovascular health and smoking
status; two sets of images comprising colour fundus and
radial pattern spectral domain OCT from two separate
visits with the corresponding visual acuity from each
visit. The two sets of images were termed baseline and
index, with the former from a visit when the lesion was
quiescent and the latter from a visit when the lesion
could have been either quiescent or reactivated.
Participants
The ECHoES trial recruited ophthalmologists and opto-
metrists working in the UK, through information circu-
lated in optometry journals and forums and to
ophthalmologists’ email lists. Ophthalmologists were
required to have 3 years’ postregistration experience in
ophthalmology, have passed the part 1 examination of
the Royal College of Ophthalmologists or the Diploma
in Ophthalmology or equivalent and have experience
within the AMD service (no minimum duration speci-
ﬁed). Optometrists were required to be fully qualiﬁed,
registered with the General Optical Council for at least
3 years and not be participating or have participated in
any AMD shared care scheme.
Training
All participants received the same training.
Ophthalmologists and optometrists are qualiﬁed to
detect retinal pathology, but optometrists may not have
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the skills to detect lesion reactivation. Although OCTs
are increasingly being incorporated into optometry prac-
tices, this would have been a completely new imaging
modality for many. Eligible ophthalmologists may also
not have been fully trained to detect lesion reactivation
since doctors without specialist skills (grade ST1 and
above) often staff retina clinics in the HES.
There were two aspects of training. First, participants
had to attend two online webinars; second, each partici-
pant had to assess a set of training vignettes and achieve
a criterion level of performance. The webinars provided
a reproducible package of background to the trial, infor-
mation about the management of nAMD and how to
assess OCT and colour retinal images for relevant fea-
tures and the trial. Each participant assessed 24 training
vignettes, randomly sampled from the vignette database
after excluding any vignette preassigned for the partici-
pant’s main trial assessments. The pass mark was set at
75% (18 of 24); if this was not attained, a second
attempt was permitted with different training vignettes,
but participants who failed to achieve the pass mark a
second time were withdrawn from the trial. Further
information, including details of the content of the lec-
tures, is available elsewhere.9
Outcomes
The primary outcome was correct classiﬁcation of the
activation status of the nAMD lesion characterised in the
vignette at the index visit, from the images and other
information the vignette contained. Participants’ classiﬁ-
cations (reactivated, quiescent or suspicious) were
judged against an expert reference standard (see
below). For the primary outcome, suspicious and quies-
cent classiﬁcations were grouped, creating a binary
outcome (reactivated vs suspicious/quiescent). A partici-
pant’s lesion classiﬁcation was scored as correct if the
participant’s classiﬁcation and the reference standard
lesion classiﬁcation matched, that is, both were ‘reacti-
vated’, or both were suspicious/quiescent.
Secondary outcomes were as follows: the frequency of
potentially sight-threatening errors (deﬁned as a ‘reacti-
vated’ vignette, based on the reference standard, classi-
ﬁed as ‘quiescent’ by a participant); participants’
judgements about the presence or absence, and increase
from baseline, of lesion components (subretinal ﬂuid,
intraretinal cysts, diffuse retinal thickening (DRT),
pigment epithelial detachment (PED), blood and exu-
dates); participant-rated conﬁdence in their decisions
about the primary outcome on a ﬁve-point scale; and
cost-effectiveness of monitoring patients with quiescent
lesions by optometrists in the community compared to
ophthalmologists in the HES. In addition, we carried
out focus groups to ascertain the views of patients, their
representatives, optometrists, ophthalmologists and clin-
ical commissioners on the proposed shared care model.
The results of the cost-effectiveness analysis and focus
groups are not described in this article.
We believed that the training would be very important
in order for participants to achieve good performance
when assessing the vignettes. Therefore, in order to help
interpret the results, we emailed a questionnaire to all
participants (n=102) who completed training to obtain
feedback about their perceptions of the quality (6-point
scale: excellent, very good, good, fair, poor and very
poor) and adequacy of the training (3-point scale: com-
pletely sufﬁcient, additional training required and com-
pletely different training required).
Reference standard
A reference standard lesion classiﬁcation was established
for each vignette based on the judgements of three
medical retina experts (UC, SPH and TP; these experts
lead the UK Network of Ophthalmic Reading Centres).
The experts agreed a framework for assigning a refer-
ence classiﬁcation (table 1), which meant that disagree-
ments between experts could only arise from
disagreements about the presence or absence of speciﬁc
features, not from disagreements in how the features
were interpreted. Using the web-based application, the
experts independently assessed the image features
without reference to participants’ assessments and classi-
ﬁed all 288 vignettes as quiescent, suspicious or reacti-
vated. A meeting was then held to establish a consensus
classiﬁcation for 69 vignettes for which experts’ inde-
pendent classiﬁcations disagreed.
During participants’ training, it was explained that the
presence or absence of certain features indicated the activ-
ity status of a lesion; the experts’ framework deﬁned how
combinations of features related to the overall assessment
of lesion activity. A set of validation rules based on the
framework was applied to the assessment system. So, when
participants entered data into the web application,9 the
system displayed a message if the combination of responses
and the chosen activity status was not consistent with the
rules. Participants were asked to conﬁrm their responses
(despite the inconsistency) or edit them.
Table 1 Framework for reference classifications
Feature Lesion reactivated Lesion quiescent
SRF on
OCT
Yes No
Or And
IRC on OCT Yes, and increased
from baseline
No/not increased
from baseline
Or And
DRT on
OCT
Yes, and increased
from baseline
No/not increased
from baseline
Or And
Blood on CF Yes, and increased
from baseline
No/not increased
from baseline
Or And
Exudates on
CF
Yes, and increased
from baseline
No/not increased
from baseline
CF, colour fundus; DRT, diffuse retinal thickening; IRC, intraretinal
cysts; OCT, optical coherence tomogram; SRF, subretinal fluid.
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Statistical analysis
We set a non-inferiority limit of 10%, assuming that
ophthalmologists would correctly classify at least 95% of
their vignettes; this limit and assumption correspond to
an OR of 0.298. We assumed that 10% poorer perform-
ance would be the maximum difference that would be
acceptable. The choice of margin was not based on
prior evidence but was appraised by ﬁve peer-reviewers,
none of whom suggested it was too large.
The sample size was estimated as recommended by Lu
and Bean.12 The calculation gave an unconditional
maximum sample size of 266 to have 90% power to test
the non-inferiority hypothesis with 2.5% (one-sided) stat-
istical signiﬁcance. This number was increased to 288 to
ensure we achieved balance in the design (ie, each
vignette assessed the same number of times, with each
assessor reviewing the same number of vignettes). We
considered lower values for the proportion correctly
classiﬁed by ophthalmologists; providing ophthalmolo-
gists classiﬁed at least 75% of vignettes correctly, the
sample size was sufﬁcient to test the hypothesis for a
margin no greater than 7.5%. We assumed for this calcu-
lation that each vignette would only be assessed once by
each professional group; in fact, each vignette was seen
by seven participants in each group, so the trial had
90% power to detect non-inferiority for a lower propor-
tion of vignettes correctly classiﬁed by ophthalmologists.
The analysis population was all participants who suc-
cessfully completed training and assessed all their main
study vignettes. Continuous variables are summarised by
means and SDs, or medians and IQRs if distributions
were skewed. Categorical data are summarised as a
number and percentage. Baseline participant character-
istics are described and groups formally compared using
t tests, Mann-Whitney tests, χ2 tests or Fishers exact tests
as appropriate.
All primary and secondary outcomes were analysed
using mixed effects regression models, adjusting for the
order in which the vignettes were viewed as a ﬁxed
effect (tertiles: 1–14, 15–28 and 29–42) and participant
and vignette as random effects. All outcomes were
binary and analysed using logistic regression with group
estimates presented as ORs with 95% CIs. For hypothesis
tests, two-tailed p values <0.05 were considered statistic-
ally signiﬁcant; likelihood ratio tests were used in prefer-
ence to Wald tests.
There were no changes to the methods for the study.
However, the questionnaire about participants’ percep-
tions of training was added shortly after starting to
recruit and the methods of analysis were changed to
accommodate the fact that experts classiﬁed some
lesions as suspicious.
RESULTS
Recruitment
Between 1 June 2013 and 6 March 2014, 155 healthcare
professionals registered their interest in the trial, and of
these, 62 ophthalmologists and 67 optometrists con-
sented to take part. A number of participants withdrew
or were withdrawn due to not completing their webinar
training, not achieving the required performance level
in their training vignettes, no longer being required or
no longer wishing to take part (ﬁgure 1). Of 56 ophthal-
mologists who started to assess training vignettes, 2 did
not complete their assessments of training vignettes and
4 failed to achieve the pass mark twice and were not
allowed to continue in the trial; 48 of the remaining 50
achieved the pass mark with their ﬁrst set of training
vignettes and 2 with their second set. Of 61 optometrists
who started to assess training vignettes, 4 did not com-
plete their assessments of training vignettes (1 because
the target number of optometrists had been attained)
and 8 failed to achieve the pass mark twice and were not
allowed to continue in the trial; 38 of the remaining 49
achieved the pass mark with their ﬁrst set of training
vignettes and 11 with their second set. As planned, 48
ophthalmologists and 48 optometrists completed the full
trial and formed the analysis population.
Reference standard classifications
The reference standard classiﬁcations for the 288 vign-
ettes were: 142 reactivated (49.3%), 141 (49.0%) quies-
cent and 5 (1.7%) suspicious.
Participant characteristics
The demographic characteristics of optometrists and
ophthalmologists were similar (mean (SD) age 43.1
(10.1) and 42.2 (8.0) years, respectively, p=0.61; 50.0%
vs 43.8% were women, p=0.54). Optometrists had more
years of qualiﬁed experience than ophthalmologists
(median (IQR) 17.4 (10.1 to 28.4) and 11.4 (4.8 to
16.9) years, p<0.001).
Primary outcome
Ophthalmologists and optometrists correctly classiﬁed
the nAMD lesion in the index images of 1722/2016
(85.4%) and 1702/2016 (84.4%) vignettes. The median
number of correct lesion classiﬁcations among ophthal-
mologists was 37/42 (IQR 35.0–38.5, minimum 26,
maximum 41) and, among optometrists, was 36/42
(IQR 33.0–38.0, minimum 24, maximum 41). The ability
of optometrists to classify lesions correctly was non-
inferior (clinically and statistically) to the ability of
ophthalmologists, according to the prespeciﬁed limit of
10% absolute difference (dotted black line in ﬁgure 2).
In this primary outcome model, the variance attributed
to the participant random effect was far smaller than
that of the vignette random effect (0.360 vs 2.062,
respectively). Participants over-ruled the validation
framework for 2.5% of all assessments (102/4032).
Optometrists were more likely to correctly classify a
vignette as reactivated than ophthalmologists (795/994
(sensitivity=80.0%) vs 736/994 (sensitivity=74.0%)), but
were less likely to correctly classify a vignette as quies-
cent/suspicious (907/1022 (speciﬁcity=88.7%) vs 986/
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1022 (speciﬁcity=96.5%); ﬁgure 3). A post hoc analysis
quantiﬁed this interaction (χ2=50.4, df 1, p<0.001)
between professional group and reference standard clas-
siﬁcation (reactivated vs quiescent/suspicious); the odds
of an optometrist being correct was ∼50% higher than
an ophthalmologist if the reference standard classiﬁca-
tion was reactivated (OR 1.52, 95% CI 1.08 to 2.15;
p=0.018), but ∼70% lower if the reference standard
classiﬁcation was quiescent/suspicious (OR 0.27, 95% CI
0.17 to 0.44; p<0.001).
Secondary outcomes
Serious sight-threatening errors could only occur for the
vignettes that were classiﬁed as reactivated by the refer-
ence standard. These errors occurred in 62/994 (6.2%)
of ophthalmologists’ classiﬁcations and 57/994 (5.7%)
Figure 1 Flow of participants. At the start of the trial, we were unsure how many participants we would need to recruit in order
to meet our target of 48 participants in each group. Therefore, we over-recruited at the consent stage and asked a number of
participants to complete the webinar and then ‘wait and see’ whether we needed them to participate in the main trial. We also
slightly over-recruited at each stage of the trial to account for withdrawals. This resulted in a small number of participants being
withdrawn at various stages of the trial because they were no longer required.
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of optometrists’ classiﬁcations (OR 0.93, 95% CI 0.55 to
1.57; p=0.789).
The three experts did not attempt to reach consensus
about the presence of lesion components in a vignette.
Therefore, participants’ responses about the presence of
lesion components were compared by professional
group, without relating these to a reference standard.
Optometrists judged lesion components to be present
more often than ophthalmologists for all components
except PED, consistent with their higher overall sensitiv-
ity. This difference was particularly evident for DRT and
exudates (table 2; ﬁgure 4).
Ophthalmologists were more conﬁdent about their
classiﬁcations than optometrists; ophthalmologists were
very conﬁdent (5 on the rating scale) for 1175/2016
(58.3%) vignettes, whereas optometrists had a similar
level of conﬁdence for only 575/2016 (28.5%) vignettes
(OR 0.15, 95% CI 0.07 to 0.32; p<0.001). For both
groups, over 90% of very conﬁdent classiﬁcations were
correct, but there was no clear relationship between con-
ﬁdence and correctness for less conﬁdent ratings.
No harms could arise in the trial because decisions
were being made for vignettes.
Among the respondents (92/102, 90%) to the ques-
tionnaire about training, the quality of the training was
perceived to be good, very good or excellent by 90% of
ophthalmologists (43/47) and 70% of optometrists
(39/55). The majority of ophthalmologist respondents
(70%) considered that the training was completely sufﬁ-
cient compared to 11% of optometrists.
DISCUSSION
Main findings
Optometrists were non-inferior to ophthalmologists with
respect to the overall proportion of lesions correctly clas-
siﬁed, but they made more cautious decisions.
Compared to ophthalmologists, they were less likely to
classify a reactivated lesion as quiescent or suspicious
and more likely to classify a quiescent or suspicious
lesion as reactivated. More cautious decision-making
may be desirable, since it minimises the risk of false-
negative misclassiﬁcations; furthermore, it is consistent
with community optometrists’ obligation under their
service contract to refer any suspected pathology,
although it limits the potential for community monitor-
ing to reduce the HES workload and be cost-effective.
The ﬁnding may also reﬂect optometrists having more
difﬁculty in interpreting the diversity of appearance of
quiescent lesions, that is, eyes with an abnormal appear-
ance but not needing treatment.
The virtual nature of the trial was certainly efﬁcient
compared to a conventional trial recruiting patients to
shared or conventional care. Recruitment of all partici-
pants, provision of training and assessment of all vign-
ettes took just under 11 months. We suspect that a
conventional trial to address the research question
would not have been feasible, regardless of the time or
Figure 2 Comparison between optometrists and
ophthalmologists for the primary outcome. The point estimate
for the effect size comparing optometrists with
ophthalmologists (reference category) for the outcome of
correct classification is shown as an odds ratio (OR) and the
error bar represents the 95% CI. (The OR of 0.91 means that
optometrists had slightly lower odds of making a correct
classification than ophthalmologists, hence the treatment
effect slightly ‘favours’ ophthalmologists.) The line of no
difference is illustrated by the solid vertical line at 1. The black
dashed line (at 0.30) represents the prespecified
non-inferiority limit of 10% poorer performance (assuming
95% of vignettes would be classified correctly by
ophthalmologists). The black dotted line (at 0.53) represents
the same non-inferiority limit of 10% but for the observed
percentage of vignettes classified correctly by
ophthalmologists (85%).
Figure 3 Participants’ lesion classifications for vignettes
classified as reactivated or quiescent by the reference
standard. Thirty-five observations in each group, for the five
vignettes classified by the reference standard as ‘suspicious’
which were each assessed by seven professionals, are not
shown in this graph. (The data are as follows—
ophthalmologists: 1=Reactivated (2.9%), 17=Suspicious
(48.6%), 17=Quiescent (48.6%); optometrists: 10=Reactivated
(28.6%), 11=Suspicious (31.4%), 14=Quiescent (40.0%)).
These data are consistent with optometrists making more
cautious retreatment decisions than ophthalmologists.
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expense, since the focus groups indicated that partici-
pants might have perceived shared care to be more
risky.9 12 It would also have had to recruit ∼500 partici-
pants to have similar power for the observed success rate
of 85% and a non-inferiority margin of 10%.
The staged nature of the trial and the risk of withdra-
wals, combined with the priority of maintaining the
balanced incomplete blocks design, made it difﬁcult to
manage recruitment efﬁciently. The limited number of
vignettes, which required us to sample training vignettes
from among the 288 vignettes used for the trial assess-
ments, meant that each participant had to be assigned
42 speciﬁc vignettes (according to the blocked design)
for the main trial before starting training. This con-
straint prevented a standby participant from progressing
in the trial until an existing participant had deﬁnitively
withdrawn and freed up a speciﬁed set of vignettes.
The difference between professions in the overall pro-
portion of vignettes correctly classiﬁed will vary depend-
ing on the proportion of vignettes classiﬁed as active by
the reference standard because optometrists tended to
make more false-positive referrals. Therefore, we consid-
ered whether the proportion of active vignettes in the
study was representative. In the IVAN trial, the lesion
was judged to be active among participants allocated to
discontinuous treatment at 30% of visits in year 1 and
27% in year 2; the median percentage within patients in
both years was 33%. Although these percentages are
lower than in the ECHoES vignette database, there are
two reasons why the percentage may well be higher in
real life than in the IVAN trial. First, active lesions in
the IVAN trial were identiﬁed using either Stratus or
Fourier domain OCT equipment; detecting activity with
the former equipment is more difﬁcult and is likely to
have underestimated the proportion of active lesions.
Second, the treatment-as-needed regimen was probably
more intensive in the IVAN trial (three treatments at
monthly intervals were mandated) than in current usual
care.
Strengths and limitations
The fact that vignettes were created from information
for actual patients, documented from diagnosis in the
context of a randomised trial, is a key strength but also
caused limitations (see below). The web application
allowed us to recruit ophthalmologists and optometrists
from across the UK and to carry out the trial quickly
and efﬁciently.
Table 2 Secondary outcomes of sight-threatening errors, identification of lesion features and confidence ratings
Ophthalmologists
(n=48) Optometrists (n=48)
OR (95% CI) p ValueSecondary outcome n Per cent n Per cent
Sight-threatening errors 62/994 6.2 57/994 5.7 0.93 (0.55 to 1.57) 0.789
Is there SRF? 515/2016 25.5 627/2016 31.1 1.73 (1.21 to 2.48) 0.002
Has it increased since baseline? 498/515 96.7 541/627 86.3
Are there IRC? 799/2016 39.6 808/2016 40.1 1.00 (0.61 to 1.65) 0.985
Has it increased since baseline? 667/799 83.5 683/808 84.5
Is there DRT? 482/2016 23.9 826/2016 41.0 3.46 (2.09 to 5.71) <0.001
Has it increased since baseline? 381/482 79.0 597/826 72.3
Is there any PED? 845/2016 41.9 842/2016 41.8 0.91 (0.47 to 1.79) 0.786
Has it increased since baseline? 311/845 36.8 392/842 46.6
Is there blood? 150/2016 7.4 194/2016 9.6 1.56 (1.00 to 2.44) 0.048
New or increased since baseline? 126/150 84.0 146/194 75.3
Are there exudates? 152/2016 7.5 380/2016 18.8 3.10 (1.58 to 6.08) <0.001
New or increased since baseline? 38/152 25.0 87/380 22.9
Confidence rating
1 7/2016 0.3 52/2016 2.6
2 26/2016 1.3 140/2016 6.9
3 220/2016 10.9 496/2016 24.6 0.15 (0.07 to 0.32)* <0.001
4 588/2016 29.2 753/2016 37.4
5 1175/2016 58.3 575/2016 28.5
Correct lesion classifications for each confidence rating†
1 3/7 42.9 42/52 80.8
2 21/26 80.8 114/140 81.4
3 147/220 66.8 362/496 73.0
4 474/588 80.6 634/753 84.2
5 1077/1175 91.7 550/575 95.7
*Comparison of optometrists versus ophthalmologists; odds of a confidence rating of 5 versus a rating of 1–4.
†For example, of the seven vignettes to which ophthalmologists gave a confidence rating of 1, three were correct with respect to the primary
outcome.
DRT, diffuse retinal thickening; IRC, intraretinal cysts; OR, odds ratio; PED, pigment epithelial detachment; SRF, subretinal fluid.
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The two main limitations of our study are the virtual
nature of the trial and the adequacy of training.
Decision-making on the basis of a vignette is different
from face-to-face decision-making in a clinic. However,
decision-making on the basis of investigations made pre-
viously, in the absence of the patient, is similar to how
some hospitals are managing their workload. More opto-
metrists than ophthalmologists had to assess two sets of
training vignettes to attain the pass mark (in effect, add-
itional training), but the results of the main trial suggest
that the combination of webinars and sets of training
vignettes was sufﬁcient to enable the optometrists to
classify lesion activity as well as the ophthalmologists.
Feedback questionnaires about training showed most
respondents thought that the quality was good but that
optometrists would have liked more training (consistent
with more optometrists needing to assess two sets of
training vignettes). The online platform used for the
trial is well suited to delivering more training,
‘refreshers’ and, potentially, interaction with experts
about images considered to be especially difﬁcult.
We were limited by the types of OCT scan that were
available as these images were acquired during the trial
using equipment and a protocol and that were optimal
at the time. Current spectral domain systems have
improved software for the visualisation of images, which
also permit alignment and comparison of scans from dif-
ferent visits. Therefore, clinicians in the HES may have
been disadvantaged if they were accustomed to inter-
preting signs of lesion activity or quiescence using more
scans than we were able to display in a vignette.
There are clear differences between ophthalmologists
and optometrists in their training, exposure to retinal
diseases and imaging technologies, which we considered
when deﬁning the eligibility criteria for participants.
Trainee ophthalmologists are exposed to retinal services
and imaging of retinal anatomy throughout their train-
ing period; all NHS clinics in the UK are now equipped
with high-resolution Fourier domain OCT systems, and
these are used extensively in the diagnosis and manage-
ment of all posterior ocular segment disorders.
Accepting that the qualiﬁcations implied different
knowledge and experience and might be acquired at
varying age/maturity, we therefore speciﬁed that partici-
pants for both professions must have had 3 years’ post
qualiﬁcation experience. We do not think that the differ-
ence between professions in the median number of
years’ experience (after obtaining the qualiﬁcation that
conﬁrmed eligibility) affected the ﬁndings. We also
trained ophthalmologists and optometrists identically.
There was a small difference between professional
groups in the proportions of participants who failed to
achieve the required standard to progress to the main
trial. These numbers are small and the difference is
uncertain. Moreover, implementation of shared care
would require a rigorous standard to be applied, as was
the case in our study; what matters with respect to imple-
mentation is that a rigorous standard should be set, at
least as rigorous as adopted for this study (since we
showed that optometrists who passed the standard for
progressing to the main trial performed as well as the
ophthalmologists who passed the standard).
The trial findings in the context of existing evidence
There is currently no evidence about the effectiveness of
community follow-up by optometrists for nAMD.
However, there is evidence about the effectiveness of
optometrists in providing ‘shared care’ with the HES for
glaucoma and diabetic eye disease and the associated
training programmes. Evaluations comparing manage-
ment by optometrists and ophthalmologists have shown
acceptable levels of agreement between the decisions
made in the context of glaucoma and accident and
emergency services.2 3 A recent review of approaches to
increase the capacity of nAMD services in the UK
described scenarios involving extended roles for opto-
metrists and nurse practitioners but only within the
HES.4 Other studies have evaluated the potential of
decision-making in the patient’s absence using OCTs
captured by outreach services but have only studied
ophthalmologists’ decisions.5 6
Taking and interpreting retinal images are skills that
can be easily taught (the former is usually carried out by
technicians in the HES), and therefore, the ﬁnal evalu-
ation in a telemedicine scenario need not always involve
an ophthalmologist. Many hospitals already involve spe-
cialist optometrists and nurse practitioners in making
clinical decisions, although the effectiveness of these
management pathways has not been formally evaluated.
Shared care in the manner envisaged in this trial
requires the ability to interpret signs in the colour and
OCT retinal images and the facility for patients to be
returned urgently to the HES when reactivation is
Figure 4 Reporting of lesion components as present. Point
estimates for different lesion components are odds ratios and
error bars are 95% CIs. Line of no difference is illustrated by
the vertical dashed line at 1. PED: pigment epithelial
detachment.
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detected. Such ability needs to be veriﬁed and regularly
updated for quality assurance.
Qualitative research carried out alongside the main
trial identiﬁed potential barriers to implementation,
including ophthalmologists’ and service users’ percep-
tions of optometrists’ competence and the need for
excellent collaborative working between optometrists
and ophthalmologists with respect to managing urgent
referrals.13 Despite these challenges, optometrists repre-
sent a highly skilled and motivated workforce in the UK,
the vast majority of whom work in the community. Many
optometric practices have invested in the equipment
required to obtain the necessary retinal images and
already use these to inform their day-to-day decisions.
An online platform such as that used for this trial could
be used to provide quality assurance during implementa-
tion of shared care and initial referral decisions could
be mentored or made jointly by optometrist and oph-
thalmologist to foster conﬁdence. A cost-effectiveness
analysis was also carried out alongside the trial and will
be reported separately.
Conclusions
The ECHoES study has demonstrated that, after appro-
priate training, community-based optometrists were as
good as HES ophthalmologists in classifying the activity
status of a lesion, but tended to make different types of
errors. The tendency of optometrists to be more cau-
tious than ophthalmologists, being less likely to misclas-
sify reactivated lesions but more likely to classify
quiescent lesions as reactivated, may be desirable in a
primary care setting.
The barriers to implementing a shared care policy based
on the model evaluated in ECHoES (above) could be
addressed by implementing continuous quality assurance of
the performance of optometrists and rapid referral to HES
alongside shared care. We do not believe that further
research involving patient participants, for example, a con-
ventional trial, is required. A web platform such as the one
developed for the ECHoES study could provide additional
training and practice in judging vignettes and quality assur-
ance of the performance of optometrists. Hospital informa-
tion systems routinely provide data to audit the timeliness of
other services (eg, cancer waiting times14) and it should be
possible to adapt them to audit rapid referral.
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